InnoDx Solutions Private Limited

Despite a vaccine and antiviral treatments are available, hepatitis B infection remains a global serious public health issue that affects 2 billion people worldwide and 350 million people harbour Hepatitis B virus HBV chronically. Rapid card and ELISA are widely used for screening HBV, but they have a large window period. Nucleic Acid based test NAT like RT-PCR are highly sensitive and specific but are expensive and are closed system setup.

InnoDx Solutions propose to develop quantitative RT-PCR kit for detecting all HBV genotypes A-H in human blood samples which will be an open system so that all small blood banks and hospitals can utilize our test for accurate quantitative HBV detection for screening and right treatment purpose.